Home/Pipeline/Sotatercept

Sotatercept

Pulmonary Arterial Hypertension (PAH)

Phase 3Active

Key Facts

Indication

Pulmonary Arterial Hypertension (PAH)

Phase

Phase 3

Status

Active

Company

Merck

About Merck

Merck & Co. is a research-intensive biopharmaceutical giant with a foundational mission to put medicine before profits, driving global health impact. Its strategic focus is on high-growth therapeutic areas, most notably oncology led by blockbuster KEYTRUDA, complemented by a robust vaccine portfolio and promising pipeline. The company leverages a multi-modal technology platform and significant financial strength to sustain innovation, navigate patent cliffs, and pursue strategic business development to fuel long-term growth.

View full company profile

Therapeutic Areas

Oncology Vaccines Immunology Cardiometabolic Infectious Diseases Neuroscience

Other Pulmonary Arterial Hypertension (PAH) Drugs

Drug	Company	Phase	Status
NTP42	ATXA Therapeutics	Phase 1	Active; Orphan Drug Designation from FDA and EMA. Phase 1 results published.
Transdermal Treprostinil Prodrug Patch	Corsair Pharma	Pre-clinical	Active
Anti-EMAP II monoclonal antibody	Allinaire Therapeutics	Pre-clinical	Active
Tiprelestat	tiakis Biotech	Phase 2	Active
Seralutinib	Chiesi	Phase 3	Active
TPIP (Treprostinil Palmitil Inhalation Powder)	Insmed	Phase 2b	Active
Ralinepag	United Therapeutics	Phase 3	Active (ADVANCE CAP)
Beraprost MR	United Therapeutics	Phase 3	Active (ISABELA)
YUTREPIA™ (treprostinil) inhalation powder	Liquidia Corporation	Approved	Approved; Commercial preparation
LIQ861 (treprostinil) inhalation powder	Liquidia Corporation	Phase 3	Active
L606 (liposomal treprostinil) injection	Liquidia Corporation	Preclinical	Investigational
CS1	Cereno Scientific	Phase II	Active; Phase IIa completed, Phase IIb in preparation